Source: PR Newswire
PRESS RELEASE Excerpts
March 27, 2014

LA JOLLA, Calif.,"2014 has the potential to be a transformative year for Auspex as our lead program SD-809 (dutetrabenazine) advances towards completion of the Phase 3 pivotal study in chorea associated with Huntington's disease (HD)," said Pratik Shah, Ph.D., President and CEO of Auspex. "Following the successful completion of our Initial Public Offering (IPO) last month, we have significantly strengthened our balance sheet and are well positioned to execute on our strategy of developing SD-809 for HD and other debilitating hyperkinetic movement disorders such as Tardive Dyskinesia (TD) and Tourette Syndrome (TS)."

Tourette Syndrome (TS): An eight-week open-label preliminary efficacy and safety clinical trial (Phase 1b) is being planned for the potential treatment of tics associated with TS. This study will involve adolescent subjects and the top-line data are expected in the fourth quarter of 2014.

About Auspex Pharmaceuticals Auspex Pharmaceuticals is a late clinical stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications. Auspex's lead product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has employed its deuterium chemistry approach to optimize other deuterium-containing compounds in its portfolio that are at various stages of development. For further information, please visit the company's website Auspex Pharmaceuticals | treatment of orphan hyperkinetic movement disorders .